Plozasiran pharmacodynamics unaffected by kidney or liver impairment

Comparable apoC3 and TG reductions are seen in patients treated with plozasiran 25 mg s.c with and without moderate-to-severe renal or moderate hepatic impairment, suggesting there is no need for dose adjustment in these groups.